# BRISTOL MYERS SQUIBB CO stock analysis

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheu

## Market evidence and data freshness

The public preview recorded BRISTOL MYERS SQUIBB CO at 63.13 USD on 2026-11-05T21:00:02.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-11-08 through 2026-11-03 across 1252 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## Published research mentioning BMY

These are separate dated research reports, not a consensus view or a current signal.

- [Night movers — Oct 14: Chip selloff deepens as healthcare takes the baton](https://commonquant.ai/research/for-you/night-movers-oct-14-chip-selloff-deepens-as-healthcare-takes--9d3ee3b7-ef34-5be7-8899-fcdc729c2e75) — 2026-10-15 UTC
- [Night movers — Oct 12: AI headlines split the overnight board as Meta's Wonder models shined while chip names stu](https://commonquant.ai/research/for-you/night-movers-oct-12-ai-headlines-split-the-overnight-board-a--eeb20837-e850-58a4-930c-0c84bc1d247d) — 2026-10-14 UTC
- [Night movers — Oct 5: Chip headlines split semis while healthcare names lag into the close](https://commonquant.ai/research/for-you/night-movers-oct-5-chip-headlines-split-semis-while-healthca--8e84a920-a43e-5c80-90b1-db66ee1ad49c) — 2026-10-06 UTC

## What should I review before buying BRISTOL MYERS SQUIBB CO stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/bmy)